Enzyme by Design Inc.
Biotech · Private
EBD-300, a next-generation mammalian L-asparaginase enzyme therapeutic with reduced immunogenicity and zero off-target glutaminase activity, engineered for longer in vivo persistence to treat acute ly
enzymebydesign.com →- Grants
- $4.2M
- 11 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20172018201920202021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · A novel glutaminase-free mammalian asparaginase with minimized immunogenicity to enable expanded use in cancer therapy | $298,305 | |
| Federal grant | Department of Health and Human Services · Phase I · A novel glutaminase-free mammalian asparaginase with minimized immunogenicity to enable expanded use in cancer therapy | $353,305 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a novel safe and efficacious biologic drug for the treatment of AML | $299,552 | |
| Federal grant | Department of Health and Human Services · Phase I · A novel glutaminase-free mammalian asparaginase with minimized immunogenicity to enable expanded use in cancer therapy | $55,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Maximizing the safety profile of a novel cancer therapeutic via the de-immunization of an engineered mammalian asparaginase | $299,939 | |
| Federal grant | Department of Health and Human Services · Phase I · Maximizing the safety profile of a novel cancer therapeutic via the de-immunization of an engineered mammalian asparaginase | $149,999 | |
| Federal grant | Department of Health and Human Services · Phase I · Extending the in vivo half-life of a novel engineered mammalian asparaginase via its binding to human serum albumin | $399,999 | |
| Federal grant | Department of Health and Human Services · Phase II · A novel glutaminase-free mammalian asparaginase with minimized immunogenicity to enable expanded use in cancer therapy | $1,156,734 | |
| Federal grant | Department of Health and Human Services · Phase II · A novel glutaminase-free mammalian asparaginase with minimized immunogenicity to enable expanded use in cancer therapy | $1 | |
| Federal grant | Department of Health and Human Services · Phase II · A novel glutaminase-free mammalian asparaginase with minimized immunogenicity to enable expanded use in cancer therapy | $836,804 | |
| Federal grant | Department of Health and Human Services · Phase I · Engineering in vivo half-life extension of a novel mammalian asparaginase to increase feasibility of pan-cancer therapy | $400,000 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1495 | GFREE BIO, LLC | — | — |
| 1496 | BEXION PHARMACEUTICALS, INC. | — | — |
| 1497 | Viewpoint Therapeutics, Inc. | — | $25M |
| 1498 | Enzyme by Design Inc. | — | — |
| 1499 | Calporta Therapeutics | — | — |
| 1500 | Atavistik Bio | — | — |
| 1501 | Ring Therapeutics | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.